

Molecular Testing in Non-Small Cell Lung Cancer Patients

Objective: Was EGFR* and ALK** testing performed for lung cancer patients with adenocarcinoma who have either select AJCC Stage III disease, Stage IV disease or an unresectable tumor of any Stage Group.

Time under Study: January 1, 2014 – December 31, 2014

Criteria: Adenocarcinoma lung patients who were treated at St Francis Hospital and who either have AJCC Stage IIIB, Stage IV disease or have an unresectable tumor of any Stage Group.

National Guidelines used: College of American Pathology (CAP), International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology (AMP) endorsed by the American Society of Clinical Oncology (ASCO)

FINDINGS	
Total # of patients with AJCC Stage IIIA (unresectable tumors), Stage IIIB or Stage IV disease	42
# of patients with evidence of EGFR/ALK testing done at SFH	40
Molecular Testing Performance Compliance	40/42=95%

Comments: (2) patients did not have evidence of molecular testing being performed:

- (1) patient had AJCC Stage IV disease.
- (1) patient had AJCC Stage IIIA disease, and received radiation therapy; progressed soon after and expired.

***EGFR: Epidermal Growth Factor Receptor**

****ALK: Anaplastic Lymphoma Kinase**